NEW ORLEANS, June 16 / PRNewswire / -- Coremed, a specialty research laboratory, is exclusively dedicated to the development of oral insulin, a goal of scientists ever since insulin was discovered 80 years ago. This is especially significant now because the rising incidence of diabetes around the world can affect hundreds of millions of people.

Since 1994, Coremed has conducted some of the most intensive pre-clinical biological trials of oral insulin anywhere, resulting in its publishing more than 20 papers at the Endocrine Society's annual meetings from 2000 to 2003.From this research, its orally delivered insulin, Intesulin™, is now gaining attention.

1. Results of biological data from the research of Intesulin™ show that it:
2. Has a similar hypoglycemic efficacy as injection.
3. Has sustained action over at least eight hours.
4. Can be delivered through the stomach at a very low dosing volume.
5. Is stable at room temperature.

Can potentially overcome the two biggest metabolic type 2 diabetic effects -- threat of rapid first-phase insulin relief and peripheral insulin resistance.

About Coremed

Founded in 1994, Coremed, Inc., is developing transmucosal insulin, based on its proprietary technology, for the treatment of diabetes mellitus. For more information, visit its web site http://www.coremedusa.com.

To the extent any statements made in this release relate to information that is not historical these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events beyond the company's control and other uncertainties are subject to various risk factors that could cause the company's actual results to differ materially from those expressed in any forward-looking statement.